Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

Three of Four HUMIRA Patients from CHARM Study in Remission at One Year

Maintained Remission at Two Years

ABBOTT PARK, Ill., May 21 /PRNewswire-FirstCall/ -- Results from an open-label extension study of two Abbott pivotal studies, CHARM and GAIN, demonstrate that adult moderate-to-severe Crohn's patients treated with HUMIRA(R) (adalimumab) achieved long-term clinical remission and clinical response, respectively, according to data presentations today at Digestive Disease Week(R) (DDW) in San Diego. DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Patients from CHARM and GAIN were followed through into a non-placebo controlled, ongoing open-label extension (OLE) trial. Patients from CHARM were followed a total of two years, and patients from the 4-week GAIN study were followed a total of one year.

The CHARM extension data demonstrated that three out of four patients (77 percent) taking HUMIRA, who were in remission at the end of the one-year pivotal study, maintained clinical remission for an additional year. The GAIN data showed that, of patients with a clinical response at four weeks, approximately 65 percent remained in clinical response at one year, and 40 percent were in clinical remission at one year. Response was measured by change in Crohn's Disease Activity Index (CDAI), a weighted composite score of eight clinical factors that evaluate patient wellness, including daily number of liquid or very soft stools, severity of abdominal pain, levels of general well-being and other measures. Clinical remission was measured as a score of less than 150 and clinical response was measured as a decline of at least 70 points from baseline.

Crohn's disease is a serious, chronic, inflammatory bowel disease that affects more than 500,000 Americans. It affects people of all ages but it is primarily a disease
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- EIP Pharma LLC ( www.eippharma.com ) today announced that ... in Alzheimer,s disease (AD) is underway.  VX-745 is an ... the alpha isoform of the protein enzyme p38 mitogen ... human genetic data demonstrate that inflammation is a major ... the science also indicates the p38 MAPK alpha mechanism ...
(Date:6/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/ssvbft/europe_ultrasound ) ... Devices Market - Growth, Trends And Forecasts (2014 - ... the European market is dominated by the likes of ... and Germany . This ... diseases in these regions. The European Ultrasound ...
(Date:6/2/2015)... 3, 2015 Today, the world,s ... As markets become ever more transparent, the importance of ... recognised long ago. Its maxim of "innovation brings progress ... and digitisation. The company has long been ... of the art" technology and modern approach, while also ...
Breaking Medicine Technology:EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3European Ultrasound Devices Market Report 2015-2019 2
... Nov. 4, 2011,   A unique treatment involving the ... John Hospital and Medical Center. SJH&MC is the first ... 20 centers nationwide to offer the treatment. ... has applications for a number of advanced cancers that ...
... 4, 2011   Research led by St. Jude Children,s Research ... protein interactions that are the workhorses of cells and, ... development target. The discovery involves a chemical ... of human proteins have this chemical added to the ...
Cached Medicine Technology:St. John Hospital 1st in Region to Offer Innovative Chemotherapy Delivery System 2Molecule Serves as a Key in Some Protein Interactions 2Molecule Serves as a Key in Some Protein Interactions 3
(Date:6/3/2015)... Tampa, FL (PRWEB) June 03, 2015 For ... Ads, LLC, ( http://myclassifiedads.net ), a full-service advertising agency, has ... Greater Tampa Chamber of Commerce. , MCA has been selected ... Year” Awards. The company will be honored at a luncheon ... 16 at the Tampa Museum of Art. , “This luncheon ...
(Date:6/3/2015)... TN (PRWEB) June 03, 2015 According ... Inquisitr police officers intercepted fake oxycodone pills which ... pills were doctored to look legitimate, and even sported ... officers are warning those consuming 30 mg oxycodone to ... the pills online or buy them illegally on the ...
(Date:6/3/2015)... Acne is the same wherever it appears. But ... eliminate and hard to prevent. As with acne on the ... adults, in the years when the sebaceous glands are most ... Bashian, director and lead medical aesthetician of Simply Posh ... acne are caused by oil and dead skin clogging the ...
(Date:6/3/2015)... Implant design can have a profound influence on the ... an implant surface. The unique triangular-shape of the V3 ... regeneration, resulting in the gain of greater volume of ... more esthetic restorations. , “It’s all in the shape”, ... triangular neck of the V3 provides solid anchorage at ...
(Date:6/3/2015)... Minneapolis, MN (PRWEB) June 03, 2015 ... new wellness "events" programming module. With this highly ... up, run and report on many components of its ... service at no additional charge. , With this new ... (1) Integrate DE challenges, (2) Create participant surveys, (3) ...
Breaking Medicine News(10 mins):Health News:My Classified Ads Has Been Selected as a Semi-Finalist for the 2015 ‘Small Business of the Year’ Awards 2Health News:My Classified Ads Has Been Selected as a Semi-Finalist for the 2015 ‘Small Business of the Year’ Awards 3Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Back Acne: Tips for Clearer Summer Skin 2Health News:Back Acne: Tips for Clearer Summer Skin 3Health News:MIS Implants Launches Radically New V3 Dental Implant For Immediate Biological Benefits 2Health News:DailyEndorphin Launches Wellness "Events" Portal 2
... mutations cause superoxide dismutase to clump up in motor ... A protein dysfunction could help drive amyotrophic lateral sclerosis ... a study by researchers at Brandeis University and Harvard ... caused by the death of motor neurons in the ...
... 29 DoctorDirectory.com, Inc.,announced that it ... to,co-market VoSpire ER(R) (Albuterol Sulfate) Extended-Release ... IncreaseRx utilizes,web-based educational and promotional tactics ... prescribers with targeted sales and marketing ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... on Tuesday, August 5, 2008 at 4:30 p.m. Eastern ... call and webcast,will follow the release of the second ... To access the live conference call on August ...
... some of the options available to people with disabilities when ... Disability Insurance. , ... Belleville, IL ... for food and healthcare are triggering a financial overload for ...
... digital signature solution is implemented by the South Carolina Department ... signature company, ARX (Algorithmic Research), the comprehensive mental healthcare provider ... , ... San Francisco, CA (PRWEB) ...
... 29 2008) Bariatric surgery patients treated at ... lower chance of experiencing serious complications compared to patients ... a study released today by HealthGrades, the nations leading ... the quality ratings of hospitals performing bariatric surgery in ...
Cached Medicine News:Health News:Scientists ID 'Jekyll-Hyde' Protein in Lou Gehrig's Disease 2Health News:DoctorDirectory to Co-market VoSpire ER(R) with DAVA Pharmaceuticals, Inc. 2Health News:Genomic Health to Announce Second Quarter 2008 Financial Results and Host Conference Call on Tuesday, August 5, 2008 2Health News:People with Disabilities Seek Ways to Manage Higher Healthcare Costs 2Health News:People with Disabilities Seek Ways to Manage Higher Healthcare Costs 3Health News:People with Disabilities Seek Ways to Manage Higher Healthcare Costs 4Health News:People with Disabilities Seek Ways to Manage Higher Healthcare Costs 5Health News:CoSign Digital Signature Healthcare Solution for South Carolina Department of Mental Health 2Health News:CoSign Digital Signature Healthcare Solution for South Carolina Department of Mental Health 3Health News:CoSign Digital Signature Healthcare Solution for South Carolina Department of Mental Health 4Health News:Bariatric patients have 65% lower chance of complications at top hospitals: HealthGrades study 2Health News:Bariatric patients have 65% lower chance of complications at top hospitals: HealthGrades study 3
... benchtop ductless exhaust hood ventilates and ... indoor release of exhaust. Bonded charcoal ... 28" of vertical clearance (with access ... polypropylene spill tray; options include final ...
... spot fume hood mounts on a standard ... 12.7mm (10" x 1/2" ) mounting rod. ... is placed above the source of fumes. ... tubing which connects to an aspirator or ...
This fume hood features a one-piece shell molded of polyethylene with a clear acrylic panel that slides on inside tracks. It can be set in an open, closed or intermediate position....
These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available....
Medicine Products: